Vilanti Dry Powder Inhalation Capsule
Vilanterol + Fluticasone furoate
25mcg + 200mcg
Square Pharmaceuticals Ltd.
| Pack size | 20’s Pack |
|---|---|
| Unite Price | 30.00 BDT |
Indications
Vilanti Dry Powder Inhalation Capsule is used for:
Chronic Obstructive Pulmonary Disease (COPD), Asthma
Adult Dose
Chronic Obstructive Pulmonary Disease
Indicated for long-term, once-daily, maintenance treatment of airflow obstruction with COPD, including chronic bronchitis and/or emphysema; also approved to reduce COPD exacerbations
25 mcg/100 mcg (1 actuation) inhaled PO once daily
Asthma
Indicated for once-daily treatment of asthma for patients not adequately controlled on a long-term asthma control medication (eg, inhaled corticosteroid), or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a long-acting beta agonist (LABA)
Prescribe strength (25 mcg/100 mcg or 25 mcg/200 mcg per actuation) once daily via oral inhalation
Hepatic impairment: No dosage adjustment required
Child Dose
Renal Dose
Renal impairment: No dosage adjustment required
Administration
After inhalation, rinse mouth with water and expectorate to help reduce risk of oropharyngeal candidiasis
Take at same time each day
Do not exceed 1 administration/24 hr
Contra Indications
Hypersensitivity to drug, any components/excipients, or milk proteins
Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required
Precautions
Do not use to treat acute asthma symptoms or an acute exacerbation in COPD. Discontinue immediately if paradoxical bronchospasm occurs. Cardiac arrhythmias (eg, supraventricular tachycardia & extrasystoles). Systemic effects may occur w/ inhaled corticosteroids particularly at high doses prescribed for long periods.
Patient w/ pulmonary TB or in patients w/ chronic or untreated infections. Visual disturbances may occur. History of or w/ risk factors for DM. Pneumonia in patients w/ COPD & asthma. Immunosuppression. Concomitant use of long-acting β2-adrenergic agonists. Hepatic impairment. Pregnancy & lactation. Childn <12 yr.
Pregnancy-Lactation
Pregnancy
Disease-associated maternal and/or embryofetal risk; in women with poorly or moderately controlled asthma, there is increased risk of several perinatal outcomes such as pre-eclampsia in mother and prematurity, low birth weight, and small for gestational age in the neonate; pregnant women should be closely monitored and medication adjusted as necessary to maintain optimal control of asthma
Labor and Delivery: There are no human studies evaluating effects during labor and delivery; because of potential for beta-agonist interference with uterine contractility, use during labor should be restricted to those patients in whom benefits clearly outweigh risks
Lactation
There is no information available on presence of fluticasone furoate or vilanterol in human milk; effects on breastfed child, or effects on milk production; low concentrations of other inhaled corticosteroids have been detected in human milk; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from fluticasone furoate or vilanterol or from underlying maternal condition
Interactions
Weakened or antagonized effect w/ β-adrenergic blockers. Increased systemic exposure w/ strong CYP3A4 inhibitors (eg, ketoconazole, ritonavir). Potentiated adverse reactions w/ other sympathomimetic drugs.
Side Effects
Side effects of Vilanterol + Fluticasone furoate :
1-10%
Nasopharyngitis (9%)
Upper respiratory infection (7%)
Headache (7%)
Oropharyngeal candidiasis (5%)
Mode of Action
Vilanterol: Long-acting selective beta2-adrenergic agonist (LABA); stimulates intracellular adenyl cyclase resulting in increased cAMP levels causing bronchial smooth muscle relaxation; also inhibits release of mediators of immediate hypersensitivity from cells, especially from mast cells
Fluticasone furoate (FF): Long-acting inhaled trifluorinated corticosteroid with potent anti-inflammatory activity; inhibits multiple cell types (eg, mast cells, eosinophils, basophils, lymphocytes, macrophages, neutrophils) and mediator production or secretion (eg, histamine, eicosanoids, leukotrienes, cytokines) involved in the asthmatic response
Note
Vilanti 25mcg + 200mcg Dry Powder Inhalation Capsule generic name is Vilanterol + Fluticasone furoate. Vilanti 25mcg + 200mcg Dry Powder Inhalation Capsule is manufactured by Square Pharmaceuticals Ltd.Vilanti is availble in all over Bangladesh.
Mes BD drug index information on Vilanti Dry Powder Inhalation Capsule is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.